EA200870411A1 - Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы - Google Patents

Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы

Info

Publication number
EA200870411A1
EA200870411A1 EA200870411A EA200870411A EA200870411A1 EA 200870411 A1 EA200870411 A1 EA 200870411A1 EA 200870411 A EA200870411 A EA 200870411A EA 200870411 A EA200870411 A EA 200870411A EA 200870411 A1 EA200870411 A1 EA 200870411A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
polypeptides
related methods
enhanced anti
cytotoxic properties
Prior art date
Application number
EA200870411A
Other languages
English (en)
Other versions
EA022780B1 (ru
Inventor
Джеффри В. Равеч
Канеко Йосикатус
Фальк Ниммерьян
Original Assignee
Дзе Рокфеллер Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581601&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200870411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Рокфеллер Юниверсити filed Critical Дзе Рокфеллер Юниверсити
Publication of EA200870411A1 publication Critical patent/EA200870411A1/ru
Publication of EA022780B1 publication Critical patent/EA022780B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение связано с полипептидом, содержащим по меньшей мере одну FC-область IgG, где указанный полипептид имеет более высокую противовоспалительную активность и более низкую цитотоксическую активность по сравнению с неочищенным антителом, и способы получения такого полипептида.
EA200870411A 2006-04-05 2007-04-03 СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG EA022780B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78938406P 2006-04-05 2006-04-05
PCT/US2007/008396 WO2007117505A2 (en) 2006-04-05 2007-04-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
EA200870411A1 true EA200870411A1 (ru) 2009-04-28
EA022780B1 EA022780B1 (ru) 2016-03-31

Family

ID=38581601

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870411A EA022780B1 (ru) 2006-04-05 2007-04-03 СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG

Country Status (13)

Country Link
US (14) US10167332B2 (ru)
EP (3) EP2010566B2 (ru)
JP (6) JP6084761B2 (ru)
CN (1) CN101432301B (ru)
AU (1) AU2007235413B2 (ru)
CA (1) CA2647524C (ru)
EA (1) EA022780B1 (ru)
HK (1) HK1124074A1 (ru)
IL (1) IL194526A (ru)
MX (1) MX2008012843A (ru)
NZ (1) NZ572379A (ru)
WO (1) WO2007117505A2 (ru)
ZA (1) ZA200808900B (ru)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10844125B2 (en) 2015-03-04 2020-11-24 The Rockefeller University Anti-inflammatory polypeptides
US10894832B2 (en) 2011-12-19 2021-01-19 The Rockefeller University Anti-inflammatory polypeptides

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
MX2010011598A (es) 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
US20130058917A1 (en) 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
RU2604811C2 (ru) * 2010-05-27 2016-12-10 Мерк Шарп Энд Домэ Корп. Способ получения антител с улучшенными свойствами
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
CN105263960B (zh) 2013-04-18 2020-05-22 国家医疗保健研究所 具有降低的免疫原性的组合物
WO2014179601A2 (en) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2950241A1 (en) * 2014-06-02 2015-12-10 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
CA3031034A1 (en) 2016-08-03 2018-02-08 The Board Of Trustees Of The Leland Stanford Junior University Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
JP7030109B2 (ja) 2016-09-14 2022-03-04 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
WO2019023347A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
SG11202002093TA (en) 2017-09-13 2020-04-29 Teneobio Inc Heavy chain antibodies binding to ectoenzymes
CA3085472A1 (en) 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
MX2020006715A (es) 2017-12-27 2020-08-20 Teneobio Inc Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
EP3843772A2 (en) 2018-08-31 2021-07-07 ALX Oncology Inc. Decoy polypeptides
BR112021004680A2 (pt) 2018-09-21 2021-08-31 Teneobio, Inc. Métodos para purificar anticorpos multiespecíficos heterodiméricos
EP3863673A4 (en) * 2018-10-11 2023-01-11 Momenta Pharmaceuticals, Inc. TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS
US20210388106A1 (en) 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies that bind to cd38
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
NZ240646A (en) * 1990-11-23 1994-01-26 Gen Hospital Corp Therapeutic interference between cell adhesion proteins and their
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
CA2181787A1 (en) * 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
ATE536417T1 (de) 1999-04-15 2011-12-15 Crucell Holland Bv Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP1333032A4 (en) * 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
EP2283861B1 (en) 2000-11-20 2016-01-27 Canadian Blood Services Method for Treating Thrombocytopenia with Monoclonal IVIG
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2005033135A1 (en) * 2003-10-09 2005-04-14 Daewoong Co., Ltd. Process for purifying human thrombopoietin with high content of sialic acid
LT2380911T (lt) * 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
AU2004299053B2 (en) * 2003-12-15 2011-01-06 Alexion Pharmaceuticals, Inc. Novel anti-DC-SIGN antibodies
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2614046C (en) 2005-06-30 2018-05-15 Centocor, Inc. Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
WO2007024743A2 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
EP2455100A3 (en) 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EA022780B1 (ru) 2006-04-05 2016-03-31 Дзе Рокфеллер Юниверсити СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG
EP2091969A4 (en) 2006-10-27 2010-05-12 Univ Rockefeller POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR
DK2223108T3 (en) 2007-12-27 2016-07-18 Baxalta GmbH Methods for differentiation of plasma-derived protein from the recombinant protein in a sample

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 (en) 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10894832B2 (en) 2011-12-19 2021-01-19 The Rockefeller University Anti-inflammatory polypeptides
US11608379B2 (en) 2011-12-19 2023-03-21 The Rockefeller University Anti-inflammatory polypeptides
US11613579B2 (en) 2011-12-19 2023-03-28 The Rockefeller University Anti-inflammatory polypeptides
US10844125B2 (en) 2015-03-04 2020-11-24 The Rockefeller University Anti-inflammatory polypeptides

Also Published As

Publication number Publication date
CN101432301A (zh) 2009-05-13
IL194526A (en) 2012-04-30
JP2018118985A (ja) 2018-08-02
US20170218050A1 (en) 2017-08-03
EP2010566A2 (en) 2009-01-07
US20130273040A1 (en) 2013-10-17
JP6084761B2 (ja) 2017-02-22
WO2007117505A2 (en) 2007-10-18
AU2007235413B2 (en) 2012-08-02
MX2008012843A (es) 2009-01-19
US20170320935A1 (en) 2017-11-09
EP2010566A4 (en) 2010-05-05
US20190031737A1 (en) 2019-01-31
US20230121427A1 (en) 2023-04-20
IL194526A0 (en) 2011-08-01
JP2017002041A (ja) 2017-01-05
AU2007235413A1 (en) 2007-10-18
ZA200808900B (en) 2009-10-28
EA022780B1 (ru) 2016-03-31
US20210101961A1 (en) 2021-04-08
US10167332B2 (en) 2019-01-01
JP6989979B2 (ja) 2022-02-15
CN101432301B (zh) 2014-01-08
EP3456351A1 (en) 2019-03-20
JP2020117521A (ja) 2020-08-06
JP6686058B2 (ja) 2020-04-22
US20160176950A1 (en) 2016-06-23
JP2022031807A (ja) 2022-02-22
WO2007117505A3 (en) 2008-10-16
US20100278808A1 (en) 2010-11-04
CA2647524A1 (en) 2007-10-18
CA2647524C (en) 2019-11-26
JP7357382B2 (ja) 2023-10-06
EP2815768A2 (en) 2014-12-24
EP2010566B1 (en) 2014-09-03
US20170088608A1 (en) 2017-03-30
JP6322849B2 (ja) 2018-05-16
US20170283492A1 (en) 2017-10-05
JP2015038086A (ja) 2015-02-26
US20190031738A1 (en) 2019-01-31
HK1124074A1 (en) 2009-07-03
EP2815768A3 (en) 2015-01-14
US20190127446A1 (en) 2019-05-02
US20140323696A1 (en) 2014-10-30
NZ572379A (en) 2012-06-29
EP2010566B2 (en) 2017-07-26
US20200385443A1 (en) 2020-12-10
JP2009532477A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
EA201070739A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
NL301089I2 (nl) imlifidase
ES2694564T3 (es) Polipéptidos de interleucina-2 mutantes
MY157173A (en) Modified humanised anti-interleukin-18
IL245478B (en) Regulatory t-cell epitopes, their preparations and uses
EA200702008A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
MX2013014961A (es) Variantes anticuerpos y usos de las mismas.
NZ588457A (en) Humanized anti-factor d antibodies and uses thereof
TW200732350A (en) Methods for generating monovalent IgG
PA8645301A1 (es) Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
WO2006094192A3 (en) Humanized l243 antibodies
ATE512988T1 (de) Antikörper gegen epcam und anwendungen davon
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung